Echinacea Angustifolia (AnxioCalm) in Anxiety
A Phase 2 Randomized, Double-Blind, Parallel-Group, Placebo Controlled Fixed-Dose Study of Echinacea Angustifoliae Root Extract (AnxioCalm) in Healthy Subjects With Subthreshold Symptoms of Anxiety
Sponsor: EuroPharma, Inc.
Terminated
Recruitment error; Inclusion criteria not met
Other Generalized Anxiety Disorder trials with similar outcome
A PHASE2 clinical study on Generalized Anxiety Disorder, this trial is terminated or withdrawn. The trial is conducted by EuroPharma, Inc. and has accumulated 10 data snapshots since 2018. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Terminated PHASE2
Status: Suspended → Terminated
-
Jan 2021 — Apr 2022 [monthly]
Suspended PHASE2
-
Jan 2020 — Jan 2021 [monthly]
Suspended PHASE2
Status: Completed → Suspended
▶ Show 5 earlier versions
-
Aug 2019 — Jan 2020 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Jun 2019 — Aug 2019 [monthly]
Recruiting PHASE2
-
Aug 2018 — Jun 2019 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — Aug 2018 [monthly]
Not Yet Recruiting PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- EuroPharma, Inc.
- Simon Khechinashvili University
For direct contact, visit the study record on ClinicalTrials.gov .